The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, ...

Danish biotech Genmab reported a 25% rise in its total revenue to $1.02 billion during the third quarter of 2025, ahead of analysts’ expectations for $966 million.

November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab's proposed acquisition of Merus N.V. (Merus)Genmab revenue increased ...

Genmab ( ($GMAB) ) has issued an announcement. On November 6, 2025, Genmab announced its financial results for the first nine months of 2025, ...

Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Jefferies Global ...

Genmab A/S(Nasdaq: GMAB)today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell ...

Many investors, and at least a few analysts, continued to be positive on the biotech following its just-announced acquisition. It's buying peer Merus in a deal pegged at $8 billion. Not surprisingly, ...

Genmab’s $8 billion all-cash acquisition of Merus, advised by A&O Shearman, Latham & Watkins, NautaDutilh and Kromann Reumert, is one of the largest European biotech deals to date. A&O Shearman, ...

Biotech company Genmab announced Sept. 29 it entered into an agreement to acquire all shares of Merus. The all-cash transaction is worth approximately $8 billion. Genmab is an international ...